Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 4, 2016
Reporting Period: Quarter ended June 30, 2016
This filing serves as a notification that the company announced its financial results for the second quarter of 2016. The detailed financial data is contained within a press release furnished as Exhibit 99.1, which is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the press release (Exhibit 99.1) but are not present in the body of this Form 8-K.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It only confirms the announcement of results for the quarter ended June 30, 2016.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risks, contingencies, or unusual items. The filing explicitly states that the information in Item 2.02 (including the press release) is furnished and not filed, limiting the scope of this specific document to a notification of the announcement.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 4, 2016) for actual revenue, net loss, and cash position figures.
- Verify the specific clinical trial progress and regulatory updates mentioned in the press release, as these are critical for a biopharmaceutical company.
- Confirm the company's cash runway and burn rate as detailed in the full financial statements referenced in the press release.
- Check for any updated guidance on product launch timelines or partnership milestones.